# Learning


## Why learn at all?
With increasing experience on CTAs or INDs, there may be associations between "success" metrics and certain formal characteristics of application materials. According to [BfArM](https://www.bfarm.de/EN/BfArM/_node.html) there are 3,647 applicatioin for 2014-2018,




<!---
![Please refer directly to source of origin. [BfArM 2019](https://www.bfarm.de/DE/Arzneimittel/Arzneimittelzulassung/KlinischePruefung/Genehmigungs-Verfahren/Statistik.html)](https://www.bfarm.de/SharedDocs/Bilder/Arzneimittel/klinPr/Statistik2014-2018.jpg?__blob=normal&v=3){width=450px}


![Please refer directly to source of origin. [Pei 2019](https://www.pei.de/EN/information/license-applicants/clinical-trial-authorisation/statistics/statistics-clinical-trials-node.html)](https://www.pei.de/SharedDocs/Bilder/EN/license-applicants/overview-all-requests.jpg?__blob=thumbnail&v=10){width=450px}
-->


### Limitations
This kind of data is from [grey literature](https://en.wikipedia.org/wiki/Grey_literature). Although the data is scraped from the web, it can be seen as an "official" release by federal institutions. However, no [API](https://en.wikipedia.org/wiki/Application_programming_interface) is available and the scope and breadth of the data is very limited which severely hampers knowledge from past experience.

[NCATS](https://pubs.acs.org/doi/pdf/10.1021/acsptsci.9b00056)

## What to learn first?
“Information gain per capita of accepted research burdens” is an useful concept. 
[Intriguing](http://serayamaouche.net/code/R/Rcode.html)

## How to learn best?




